Cologne's biotech centre BioCampus is branching out from its original purpose. Director André van Hall tells Natasha Turak why an interdisciplinary approach is the way forward.
- Alternative/Renewable energy
- Automotive Components
- Automotive OEM
- Building & Construction Materials
- Business Machines & Equipment
- Business Services
- Ceramics & Glass
- Coal, Oil & Natural Gas
- Consumer Electronics
- Consumer Products
- Electronic Components
- Engines & Turbines
- Financial Services
- Food & Tobacco
- Hotels & Tourism
- Industrial Machinery, Equipment & Tools
- Leisure & Entertainment
- Medical Devices
- Non-Automotive Transport OEM
- Paper, Printing & Packaging
- Real Estate
- Software & IT Services
- Space & Defence
- Warehousing & Storage
- Wood Products
Building an innovation culture can help countries prepare for the outbreak of diseases such as Ebola, write Rachel Chu and Meir Pugatch of Pugatch Consilium.
The rapid growth of Alvogen is impressive by any standards, but for a company operating in the ever-changing pharmaceuticals market it is even more remarkable. The secret of Alvogen's success lies in its decision to expand and diversify its company function, its product line and its geographical markets.
Allegations of corruption have dealt a blow to several international pharmaceutical companies operating in China. Despite this, the long-term prognosis for the industry remains good, with huge growth potential in what is set to become the world's second largest drugs market by 2016.
The Chinese city of Tianjin may lie in the shadow of investment behemoths Beijing and Shanghai, but it is still at the forefront of the country’s high-tech focus, with the Tianjin Economic-Technological Development Area central to its strong FDI appeal.
Investment into the state of New York is naturally dominated by New York City, leaving the likes of Buffalo and Rochester trailing in its wake. However, after years of decline, the two cities look to be on the cusp of a revival, thanks in no small part to the state governor's ambitious investment plans.
Experts are warning that EU policy on clinical trials in Europe could hamper innovation and investment, and stifle growth.
fDi Intelligence has a portfolio of related products that enable you to get the targeted foreign investment information you need for your role:
For real-time crossborder greenfield investment data on all sectors and locations, click here
To benchmark locations for investment projects, click here
For bespoke reports on companies, locations or sectors, click here
Most popular content